Fabtech Technologies is a company that builds entire pharmaceutical factories from scratch - not just the shell, but the sterile interiors, the machinery that makes the medicine, and the systems that purify the air and water - and hands over a working, regulation-ready facility to the client, all under a single contract. It was born from three decades of engineering work in emerging markets, and its recurring approach is to eliminate the chaos of multiple vendors by manufacturing the three critical lifelines of any drug plant - process equipment, cleanrooms, and water systems - in-house, so the client deals with one accountable partner instead of a dozen. That integrated, design-led model, delivered in hard-currency contracts across 62 countries, is the thread that runs through everything the company does.
Business segments
A single engine - turnkey life-sciences infrastructure - delivered across human pharmaceuticals, animal health, and an emerging green-energy overlay, all built on the same in-house manufacturing backbone.
1. Turnkey pharma factories: a single-accountability builder for emerging markets
The company designs, equips, and commissions complete drug-manufacturing facilities, taking end-to-end responsibility so that a client in Lagos or Riyadh gets a working, regulation-ready plant without having to stitch together a dozen separate contractors.
- Three pillars made in-house - it manufactures the process equipment that makes the medicine, the cleanroom panels and air-handling units that keep the environment sterile, and the purified-water systems that feed the production line, which means it controls the "critical lifelines" of a biopharmaceutical facility without depending on external vendors.
- Regulation-ready from the blueprint - every project is engineered to meet global standards like WHO, EU-GMP, USFDA, and UKMHRA guidelines from the first drawing to the final validation, so the client gets a facility that is built for compliance, not retrofitted for it later.
- Paid in dollars, triggered by shipment - revenue is recognised on project progress, with the bill of lading against the LC being the trigger, and all billing is in USD, which shields the company from the currency devaluation risk that plagues its operating markets.
- An 18-to-24-month promise - the typical project cycle runs from a year and a half to two years, with specific jobs ranging from an 11-month animal-vaccine facility in Saudi Arabia to a 23-to-27-month tablet-capsule plant in West Africa, giving clients a predictable timeline.
- The order book is the forward story - with a consolidated order book above ₹900 crore as of March 2026, the company has revenue visibility stretching roughly two years ahead, and it does not announce a project until a letter of credit is in hand, treating that as the only reliable sign of a real start.
2. Animal health: the same factory logic, applied to veterinary medicine
Using the identical turnkey model, the company has moved into building vaccine and formulations plants for the animal-health industry, opening a new customer set with the same in-house manufacturing engine.
- A vaccine fill-finish entry - the company secured a vaccine fill-finish facility project, marking its move beyond human pharmaceuticals into the veterinary segment, where the same GMP (Good Manufacturing Practice) standards apply.
- Saudi Arabia in under a year - a $7.8 million turnkey project for an animal-vaccine facility, covering cleanrooms, HVAC, MEP, and utilities through to handover, with an 11-month execution timeline, showed the model could be adapted to a faster, animal-health cycle.
- North Africa opens the EU door - a veterinary formulations facility in North Africa, targeted for completion by early FY27, is being built to EU-GMP standards, which would let the client export to the European Union and neighbouring African markets, making it a gateway project as much as a factory.
3. Green-energy overlay: wiring renewable power into the factory package
Through a partnership with a renewable-energy group, the company is beginning to offer clients factories that run on solar, wind, or battery-stored power - adding an energy layer to its turnkey promise without having to build that capability itself.
- Clean power bundled in - under an MoU with KP Group, every project Fabtech executes can now be powered by renewable energy, with the partner providing and integrating solar, wind, hybrid, battery storage, and even green-hydrogen solutions into the company's pharma and biotech facilities.
- A shield against diesel and grid risk - by embedding renewable power into the infrastructure from the start, the offer reduces clients' exposure to unreliable grids and volatile fuel costs in emerging markets, which matters in regions where power interruptions can ruin a sterile batch.
- Pre-engineered buildings close the loop - the company is also exploring hybrid solutions that combine pre-engineered building structures with solar integration, via partnerships with firms like Optech, under initiatives it calls Operation Greenfield and Green Shield, aiming to control the civil-infrastructure timeline that often delays project starts.
Group structure and partners
The listed parent company operates through a web of wholly owned subsidiaries in the UAE and Saudi Arabia, plus strategic minority stakes in specialist equipment makers, creating a local-execution footprint without bloating the balance sheet.
- Local subsidiaries for local trust - Fabtech Technologies Limited owns 100% of entities in the UAE (FTS) and Saudi Arabia (Fabtech Saudi), and is investing a further AED 1,00,000 into its Sharjah subsidiary to deepen its Gulf presence, because the company sees local incorporation as essential for winning trust and accessing contracts in GCC markets.
- A Saudi step-down for non-pharma work - in June 2026, the Sharjah subsidiary signed a shareholders' agreement to create a new Saudi company, Specialized Contracting Activities LLC, with Fabtech holding 51%, which will pursue mechanical, electrical, and plumbing contracts outside the pharma sector, diversifying the group's project base.
- Minority stakes that fill capability gaps - a 33% stake in Mark Maker gives access to granulation and oral-solid-dose process lines, a 49% stake in FABL Technologies provides containment solutions for high-potency projects like oncology and vaccines, and a roughly 16% stake in TSA (which the company is exiting) supplied water systems across its pharma projects, so the group gets specialist equipment without having to build every niche in-house.
- A separately listed India sibling - Fabtech Technologies Cleanrooms Ltd (FTCL) is an independent listed entity focused on India's cleanroom market, serving pharma, biotech, semiconductor, and green-energy clients with FM Global-certified modular solutions, while Fabtech Technologies Ltd concentrates on international turnkey life-sciences projects, keeping the two businesses distinct in geography and scope.